What is Zacks Research’s Estimate for TNXP FY2028 Earnings?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Equities researchers at Zacks Research issued their FY2028 earnings per share estimates for shares of Tonix Pharmaceuticals in a research note issued on Monday, March 23rd. Zacks Research analyst D. Bautz expects that the company will earn $1.97 per share for the year. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($1,762.50) per share.

TNXP has been the subject of a number of other research reports. Wall Street Zen raised shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Tonix Pharmaceuticals Stock Performance

NASDAQ:TNXP opened at $13.75 on Wednesday. Tonix Pharmaceuticals has a 52 week low of $13.07 and a 52 week high of $69.97. The firm’s 50-day simple moving average is $15.50 and its 200 day simple moving average is $18.11. The firm has a market cap of $184.25 million, a price-to-earnings ratio of -0.96 and a beta of 1.88.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its earnings results on Thursday, March 12th. The company reported ($3.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative return on equity of 60.15% and a negative net margin of 946.22%.The firm had revenue of $5.39 million for the quarter, compared to analyst estimates of $2.97 million.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Legal & General Group Plc bought a new stake in shares of Tonix Pharmaceuticals during the 2nd quarter worth approximately $25,000. Strs Ohio increased its stake in Tonix Pharmaceuticals by 9.9% in the fourth quarter. Strs Ohio now owns 7,800 shares of the company’s stock valued at $122,000 after acquiring an additional 700 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in Tonix Pharmaceuticals during the second quarter valued at approximately $28,000. Rhumbline Advisers raised its position in Tonix Pharmaceuticals by 8.0% during the third quarter. Rhumbline Advisers now owns 12,206 shares of the company’s stock valued at $295,000 after purchasing an additional 908 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Tonix Pharmaceuticals by 32.7% during the third quarter. Bank of America Corp DE now owns 4,651 shares of the company’s stock worth $112,000 after purchasing an additional 1,146 shares during the last quarter. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Seth Lederman purchased 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The stock was acquired at an average price of $14.89 per share, with a total value of $223,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,001 shares in the company, valued at $223,364.89. This trade represents a 1,500,000.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.03% of the stock is currently owned by company insiders.

Key Headlines Impacting Tonix Pharmaceuticals

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: Tonix announced the first participant was dosed in an investigator‑initiated Phase 1 pharmacodynamic study of TNX‑1900 (intranasal potentiated oxytocin) to assess potential for migraine and craniofacial pain. The program targets trigeminal neurovascular reactivity and uses laser speckle contrast imaging (LSCI) to measure forehead skin blood flow; preclinical data show intranasal oxytocin can block CGRP release, suggesting a mechanism distinct from existing CGRP drugs — a meaningful clinical/commercial differentiator if clinical signals are positive. Read More.
• Neutral Sentiment: Media outlets (Yahoo/Business Insider/TipRanks) are carrying the dosing news, increasing visibility for the TNX‑1900 program but with the caveat that this is an early, investigator‑initiated PD study rather than a registrational trial. Read More.
• Negative Sentiment: Zacks Research substantially lowered near‑ and medium‑term EPS forecasts (FY2026 and FY2027 cuts), reflecting expectations of continued large losses and cash consumption; the firm now models deep negative EPS for 2026 and reduced FY2027 projections. Those downgrades (and Tonix’s prior quarterly EPS miss and negative margins) increase the risk that the company will need to raise capital, which could dilute shareholders and pressure the stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.